LONDON–(BUSINESS WIRE)– #GlobalOpticalBiometryDevicesMarket–The global optical biometry devices market is poised to grow by USD 83.77 million during 2019-2023
Author: Business Wire
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced th…
AIS Healthcare Acquires Ophthalmology Compounding Pharmacy Hunt Valley PharmaLAB
DALLAS–(BUSINESS WIRE)–AIS Healthcare has announced the acquisition of Hunt Valley PharmaLAB (“Hunt Valley”), a 503A compounding pharmacy focused on ophthalmology medications. Already the leading targeted drug delivery (TDD) and infusion care provide…
テジ・コーリ財団が2035年までの角膜失明排除を実現する新しいプロジェクトの育成を目指す
ロンドン–(BUSINESS WIRE)–（ビジネスワイヤ） — テジ・コーリ財団は、世界で角膜失明を排除する可能性を持つプロジェクトのシード資金を提供して資金調達を推進するための新しい事業育成制度を確立します。角膜失明の予防、治療、治癒に向けた明確な道筋を持つ商業プロジェクトと非商業プロジェクトの両方が、資金、実用的なリソース、知的資本を利用できるようになります。資金提供の決定は、医療サービスが不十分な世界の貧困地域社会で2035年までにプロジェクトが及ぼすであろう総合的な影響の重大性、およ…
Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today will host the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development u…
Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the present…
Tej Kohli基金會尋求孵化能在2035年之前消滅角膜失明的新專案
倫敦–(BUSINESS WIRE)–(美國商業資訊)–Tej Kohli基金會(The Tej Kohli Foundation)將建立新的孵化器，為有望在全球消滅角膜失明的專案提供種子和加速資金。具有預防、治療和治癒角膜失明清晰途徑的商業和非商業專案均可申請資金、實際資源和智慧資本；撥款決定係依據專案在2035年之前可能對全球貧困和欠缺服務社區的總體影響程度以及專案成功的可能性。 Tej Kohli基金會繼續確立其為全球多專業中心的地位，專注於開發和促進用於預防和消滅角膜失明的可負擔、可推…
Tej Kohli基金会寻求孵化能在2035年之前消灭角膜失明的新项目
伦敦–(BUSINESS WIRE)–(美国商业资讯)–Tej Kohli基金会(The Tej Kohli Foundation)将建立一个新的孵化器，为有望在全球消灭角膜失明的项目提供种子和加速资金。具有预防、治疗和治愈角膜失明清晰途径的商业和非商业项目均可申请资金、实践资源和智力资本；拨款决定依据项目在2035年之前可能对全球贫困和服务欠缺社区的总体影响程度以及项目成功的可能性。 Tej Kohli基金会继续确立其作为全球多学科中心的地位，专注于开发和促进预防和消灭角膜失明的可负担、可推…
Tej Kohli Foundation will neue Projekte ausarbeiten, die Hornhautblindheit bis 2035 beseitigen können
LONDON–(BUSINESS WIRE)–Die Tej Kohli Foundation will einen neuen Inkubator einrichten, um Projekte mit dem Potenzial, weltweit zur Beseitigung von Hornhautblindheit beizutragen, mit Start- und Beschleunigungsfinanzierung zu unterstützen. Finanzmittel…
La Fondation Tej Kohli cherche à incuber de nouveaux projets susceptibles d'éliminer la cécité cornéenne d'ici 2035
LONDRES–(BUSINESS WIRE)–La Fondation Tej Kohli va créer un nouvel incubateur pour fournir des fonds de démarrage et d’accélération à des projets susceptibles de contribuer à l’élimination de la cécité cornéenne dans le monde entier. Des financements,…
Fundação Tej Kohli incuba novos projetos que podem eliminar a cegueira da córnea até 2035
LONDRES–(BUSINESS WIRE)–A Fundação Tej Kohli deve estabelecer uma nova incubadora para fornecer o financiamento de sementes e aceleração para projetos com potencial para ajudar a eliminar a cegueira corneana em todo o mundo. Financiamento, recursos p…
Global Ophthalmic Drugs Contract Manufacturing Market Study, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules),…
La Fundación Tej Kohli busca incentivar nuevos proyectos que permitan eliminar la ceguera corneal para el año 2035
LONDRES–(BUSINESS WIRE)–La Fundación Tej Kohli va a fundar un nuevo centro incubador para proporcionar financiación inicial y de aceleración a proyectos con el potencial de ayudar a eliminar la ceguera corneal en todo el mundo. La financiación, los r…
Polarized Sunglasses Market 2019-2023 | Rising Product Premiumization Due to Increased Innovation and Portfolio Extension to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalPolarizedSunglassesMarket–The polarized sunglasses market is poised to grow by USD 1.77 bn during 2019-2023
Riassunto: La Tej Kohli Foundation punta a incorporare nuovi progetti che potrebbero eradicare la cecità corneale entro il 2035
LONDRA–(BUSINESS WIRE)–La Tej Kohli Foundation formerà un nuovo incubatore per offrire finanziamenti di avviamento e velocizzazione ai progetti dotati del potenziale per eliminare globalmente la cecità corneale. Il testo originale del presente annunc…
Samenvatting: Tej Kohli Foundation probeert nieuwe projecten te incuberen die hoornvliesblindheid tegen 2035 kunnen elimineren
LONDEN–(BUSINESS WIRE)–De Tej Kohli Foundation moet een nieuwe incubator oprichten om zaad- en versnellingsfinanciering te verstrekken aan projecten met het potentieel om cornea blindheid wereldwijd te helpen elimineren. Financiering, praktische midd…
Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 2035
LONDON–(BUSINESS WIRE)–The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capit…
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance w…